Date: 2017-02-03
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Chemigen (USA - IN)
Product: CC100
Action mechanism:
Disease: amyotrophic lateral sclerosis (ALS)
Therapeutic area: Neurodegenerative diseases
Country: USA
Trial
details: Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days. Subjects are required to stay in the clinic for approximately 9 hours following the first and last dose. Subjects will also have a mid-week clinic visit and will be contacted by phone within 3 to 5 days after the last dose. (NCT03049046)
Latest
news: * On February 1, 2017, a Phase 1 trial sponsored by Chemigen was published on the NIH website ClinicalTrials.gov for CC100 and is currently recruiting participants. Last year, the FDA has awarded a clinical trial research grant of about $243 000 for one year to support the phase 1 study of CC100 for the treatment of amyotrophic lateral sclerosis.
